Liraglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), has a dual indication for treatment of both type 2 diabetes mellitus (T2DM) and weight loss treatment. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.